ArticleEmerging microbes & infections2022
Possible recombination between two variants of concern in a COVID-19 patient.
Open access · goldAbstract readLetter
In one paragraph
Article in Emerging microbes & infections, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Comparative Assessment of Viral Load Retention in Surgical and Fabric Masks Worn by COVID-19 Patients.Viruses · 2025Article
- A high precision and speed question answering system about the post-COVID-19.Scientific reports · 2025Article
- Review
- Data-driven recombination detection in viral genomes.Nature communications · 2024Article
- Omicron vs. the rest: Assessing the competitive dynamics and coinfection scenarios of COVID-19 strains on a social network.PloS one · 2024Article
- "Nano COVID-19": Nanopore sequencing of spike gene to identify SARS-CoV-2 variants of concern.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Analyzing the emerging patterns of SARS-CoV-2 Omicron subvariants for the development of next-gen vaccine: An observational study.Health science reports · 2023Article
- A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.Science China. Life sciences · 2023Article
- SARS-CoV-2 Recombination and Coinfection Events Identified in Clinical Samples in Russia.Viruses · 2023Article
- Identification of a rare SARS-CoV-2 XL hybrid variant in wastewater and the subsequent discovery of two infected individuals in Nevada.The Science of the total environment · 2023Article
- Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages.International journal of medical sciences · 2023Review
- Mosaic Recombination Inflicted Various SARS-CoV-2 Lineages to Emerge into Novel Virus Variants: a Review Update.Indian journal of clinical biochemistry : IJCB · 2022Review
- The SARS-CoV-2 Delta (B.1.617.2) variant with spike N501Y mutation in the shadow of Omicron emergence.Heliyon · 2022Article
- A 21L/BA.2-21K/BA.1 "MixOmicron" SARS-CoV-2 hybrid undetected by qPCR that screen for variant in routine diagnosis.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2022Article
- SARS-CoV-2 Variability in Patients and Wastewaters-Potential Immuno-Modulation during the Shift from Delta to Omicron.Biomedicines · 2022Article
- Article
- Review
- Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape.Chinese medical journal · 2022Article
- Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events.Signal transduction and targeted therapy · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 2 countries.
Yaqing HeShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Wentai MaKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, and China National Center for Bioinformation, Beijing, People's Republic of China.
Shengyuan DangNational Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
Long ChenShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Renli ZhangShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Shujiang MeiShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.ORCID 0000-0001-5976-9058
Xinyi WeiShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Qiuying LvShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Bo PengShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Jiancheng ChenShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Dongfeng KongShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Ying SunShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Xiujuan TangShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Weihua WuShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Zhigao ChenShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Shimin LiShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Jia WanShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Xuan ZouShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Mingkun LiKey Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, and China National Center for Bioinformation, Beijing, People's Republic of China.
Tiejian FengShenzhen Research Center for Communicable Disease Control and Prevention Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
Lili RenNational Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.ORCID 0000-0002-6645-8183
Jianwei WangNational Health Commission of the People's Republic of China Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.ORCID 0000-0002-1116-4559
Chinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
We identified an individual who was coinfected with two SARS-CoV-2 variants of concern, the Beta and Delta variants. The ratio of the relative abundance between the two variants was maintained at 1:9 (Beta:Delta) in 14 days. Furthermore, possible evidence of recombinations in the
Indexed as
COVID-19SARS-CoV-2HumansRecombination, GeneticSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronaviruscoinfectionintra-host single nucleotide variationsrecombinationSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.